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Discovery and Development of Human Monoclonal Antibodies to Block RhD 
Alloimmunization During Pregnancy. 
Tushar Gupta1, Melissa Gawron1, Colby Souders1, Michael Brehm2, Dale Greiner2, Leonard 
Shultz3, Smita Jaiswal2, Sean McCauley2, Ann Dauphin2,Jeremy Luban2, Lisa Cavacini1 
1MassBiologics of the University of Massachusetts Medical School and 2University of 
Massachusetts Medical School, Worcester MA.  3The Jackson Laboratory, Bar Harbor, ME 
Exposure of an Rh negative mother to red blood cells (RBCs) of an Rh positive fetus results in 
alloimmunization and development of anti-RhD antibodies. The anti-RhD antibodies cause 
hemolytic disease of the new born babies during subsequent pregnancies. Current prophylactic 
treatment involves polyclonal anti-RhD IgG purified from plasma of humans and is administered 
in approximately 20% of pregnancies. While the current prophylaxis is effective, it involves the 
use of human plasma and non-RhD specific antibodies, thus posing a risk of transmitting 
infections and undesired antibody reactions. Moreover, there is a serious scarcity of plasma 
donors to meet the requirement of anti-RhD antibodies. In this study we propose to discover and 
develop anti-RhD monoclonal human antibodies to replace the current polyclonal prophylaxis. 
We are using humanized BLT mice (fetal CD34+ stem cells, liver and thymus) reconstituted with 
RhD negative donor material and were immunized by using adenovirus containing RhD 
transgene. Serum samples were collected after 4-6 weeks of immunization. Our results show 
that the RhD immunized mice had considerably higher titer of IgG and IgA antibodies in the 
serum compared to the control, suggesting an immune response developed upon immunization. 
Splenocytes from antibody producing mice will be fused with a human fusion partner for the 
isolation of hybridomas producing human monoclonal antibodies.  The immunoreactivity and 
functional activity of these antibodies will be discussed.   
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